Disease severity and current medications
| Characteristic | Asthma | COPD |
| (n=810) | (n=1147) | |
| ACQ score*, median (IQR) | 1.3 (1.0 to 2.0) | – |
| ACQ score category†, n (%) | ||
| ≤0.75 (well-controlled) | 219 (27) | – |
| 0.75–1.5 | 195 (24) | – |
| ≥1.5 (inadequately controlled) | 396 (49) | – |
| CAT score‡, median (IQR) | – | 26 (20 to 32) |
| CAT score category§, n (%) | ||
| 1–9 (low impact) | – | 11 (1) |
| 10–20 (medium impact) | – | 323 (28) |
| 21–30 (high impact) | – | 476 (41) |
| 31–40 (very high impact) | – | 337 (29) |
| Current asthma medication, n (%) | ||
| Budesonide/formoterol (Symbicort) (any dose) | 263 (32) | – |
| 80/4.5 HFA | 136 (17) | – |
| 160/4.5 HFA | 127 (16) | – |
| Fluticasone/salmeterol (Advair HFA or Advair Diskus) (any dose) | 429 (53) | – |
| 115/21 HFA | 113 (14) | – |
| 230/21 HFA | 80 (10) | – |
| 250/50 Diskus | 203 (25) | – |
| 500/50 Diskus | 33 (4) | – |
| Mometasone/formoterol (Dulera) (any dose) | 48 (6) | – |
| 100/25 HFA | 26 (3) | – |
| 200/25 HFA | 22 (3) | – |
| Fluticasone/vilanterol (Breo) (any dose) | 136 (17) | – |
| 100/25 Ellipta | 70 (9) | – |
| 200/25 Ellipta | 66 (8) | – |
| Current COPD medication, n (%) | ||
| LAMA or LABA | – | 337 (29) |
| Umeclidinium (Incruse Ellipta) | – | 31 (3) |
| Tiotropium (Spiriva) | – | 274 (24) |
| Olodaterol (Striverdi Respimat) | – | 11 (1) |
| Aclidinium (Tudorza Pressair) | – | 19 (2) |
| ICS/LABA | – | 593 (52) |
| Budesonide/formoterol (Symbicort HFA) | – | 263 (23) |
| Fluticasone/salmeterol (Advair Diskus) | – | 295 (26) |
| Fluticasone/vilanterol (Breo Ellipta) | – | 87 (8) |
| LAMA/LABA | – | 236 (21) |
| Glycopyrrolate/formoterol (Bevespi Aerosphere) | – | 34 (3) |
| Umeclidinium/vilanterol (Anoro Ellipta) | – | 134 (12) |
| Tiotropium/olodaterol (Stiolto Respimat) | – | 65 (6) |
| Glycopyrrolate/indacaterol (Utibron Neohaler) | – | 17 (1) |
*Average from seven questions, each scored from 0 (no impairment) to 6 (maximum impairment).
†ACQ categories were defined as described by Juniper et al.12
‡Sum of eight items scored from 0 (least severe impact on the patient’s life) to 5 (most severe impact), resulting in a total score of 0 to 40.
§CAT scores categories were defined as described by Jones et al.13
ACQ, Asthma Control Questionnaire; CAT, COPD Assessment Test; HFA, hydrofluoroalkane; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist.